APP OI

APR 0 1 2002 TECH CENTER 1600/2900 Sheet 1 of 5

ATTY DOCKET NO. SERIAL NO. 09/682,968 INFORMATION DISCLOSURE STATEMENT 20488/26-DIV APPLICANTS: Hans-Ulrich Demuth, et al. FILING DATE: ART UNIT: 1646 November 2, 2001 UNITED STATES PATENT DOCUMENTS FIL. **SUB** EXAM. **DOCUMENT DATE IF CLASS CLASS INITIAL** NUMBER DATE **INVENTOR** APPR 65 Nov 1960 Shapiro, et al. 167 2,961,377 June 1976 260 564B Ahrens, et al. 3,960,949 94.3 424 July 1995 Bredehorst, et al. 5,433,955 March 1997 MacKellar 435 68.1 5,614,379 2 514 5,624,894 **April 1997** Bodor FOREIGN PATENT DOCUMENTS **DOCUMENT DATE COUNTRY CLASS SUB** TRAN **CLASS** Y/N NUMBER C07K 14/605 Y 12.2.94 **EPO** 0 658 568 A1 Y C12N 15/16 EP 0 708 179 A2 10.13.95 **EPO** 31/425 Abstract **PCT** A61K WO 97/40832 11.6.97 Only 207/16 Y 6.8.95 **PCT** C07D WO 95/15309 Љ C07C 233/57 Abstract JP 4334357 A2 11.20.92 Only Y A61K 83/00 11.9.95 **PCT** WO 95/29691 005/00 Y **PCT** C07K WO 98/22494 5.28.98 31/155 Y WO 00/53171 9.14.00 **PCT** A61K FR C07D 207/404 N FR 2696740 10.13.92 27/00 N A61K FR 2085665 3.3.71 FR C07C 129/16 N DE DT 25 42598 A1 10.11.74 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) Campbell, I.W., "Sulphonylureas and metformin: efficacy and inadequacy," 3:33-51 (1990). Merck Index, 11th Edition, page 934, 1989. Martindale the Extra, Pharmacopoeia, Page 1619, 1996. Date: Examiner:



		1 600						SI	heet 2 of 5	
FORMEPTS 1449 INFORMATION DISCLOSURE STATEMENT					ATTY DO	OCKET N	1 0.	SERIAL NO.		
					20488/	/26-DIV		09/682,968		
					APPLICANTS: I	Hans-Ulr	rich Demuth	, et al.		
					FILING Novemb	G DATE: er 2, 200		A	ART UNIT: 1646	
				UNITED STAT	ES PATENT DOC	UMENT	ΓS			
EXAM. NITIAL			INVE	ENTOR		CLASS SUB CLASS		FIL. DATE IF APPR		
ANN		4	,935,493	June 1990	Bachovo	chin, et a	1.	530	331	
		ϵ	5,006,753	Dec 1999	Efe	endic		128	898	
		5,512,549		April 1996	Chen	ı, et al.		514	12	
				FOREIGN I	PATENT DOCUM	IENTS				
		L .	CUMENT IUMBER	DATE	COU	NTRY		CLASS	SUB CLASS	TRAN Y/N
	*	DD 296 075		11.21.91	Γ	DD		C07D	295/04	N
	*	* WO 93/08259 A2		4.29.93	P	CT		C12N	15/16	Y
	*	* WO 95/11689		5.4.95	P	СТ		A61K	37/00	Y
	*	* WO 97/45117		12.4.97	P	СТ		A61K	31/435	Y
		I	E 19616486	10.30.97		DE		A61K	39/395	N
	1				UTHOR, TITLE, I otidyl peptidase IV l					oxvlamine
		*	peptidomimetic	s," Proceedings o	of the National Acad	demy of S	Sciences of	USA, Vol. 95	, November	1998
		*	(1998-11) pp. 1 Korom, S., et a	1., "Inhibition of C	CD26/dipeptidyl pep	ptidase I	V activity in	vivo prolong	s cardiac al	lograft
			survival in rat recipient," Transplantation Vol. 63, p. 1495-1500, No. 10, May 27, 1997.							
		*	Tanaka, S., et al., "Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV," Int. J. Immunopharmacol., Vol. 19, No. 1, pp. 15-24 (1997).							
		*	Mentlein, R., et al., "Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV,							
		*	Regul. Pept. 49, (1993) pp. 133-144. Wetzl, W., et al., "Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes,"							les,"
		*	Neuropeptides, 31, (1), pp. 41-45 (1997). Wakselman, M., et al., "Inhibition of HIV-1 infection of CD 26 ⁺ but not CD26 cells by a potent							
		•	cyclopeptidic inhibitor of the DPP IV activity of CD26," Abstract P44 of the 24 th European Peptide Symposium 1996.							
		*	Willms, B., et al., "Gastric Empytying, Glucose Response, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients," JCEM 81:327-332 1996) No. 1.							
		*	Arai, H., et al., relationships:	"Synthesis of pro in vitro inhibition	lyl endopeptidase ir of prolyl endopeptic	nhibitors	and evalua n canine bro	tion of their s ain," Chemica	tructure-act	ivity naceutical
\X		MARCH.	Bulletin, Vol. 4	11, Nr. 9, 1993, pp		Doto:	6/2	a/n?		
aminer:	0	<i>1111</i>	VV \			Date:	11/2	V/U E		

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

Sheet 3 of 5

		- AV					neer 5 or 5		
INFORM		TPTO-1449 SCLOSURE ST.	ATEMENT	ATTY D	OCKET NO.	SERIAL NO. 09/682,968			
INFORM	ATION DIS	CLOSURE ST.	AIENIENI	20488/26-DIV					
				APPLICANTS:	Hans-Ulrich Demi	uth, et al.			
				FILIN	NG DATE:		ART UNIT:		
					iber 2, 2001		1646		
	4-7.917		UNITED STATE	ES PATENT DO	CUMENTS				
EXAM.	DO	CUMENT					SUB	FIL.	
INITIAL			DATE	INVENTOR	ENTOR	CLASS	CLASS	DATE IF APPR	
								71111	
			FOREIGN P	 PATENT DOCU	MENTS		<u> </u>		
	DO	CUMENT	DATE	CO	UNTRY	CLASS	SUB	TRAN	
	N	UMBER			4 8 8 1 4		CLASS	Y/N	
	OTHER D	OCUMENTS ((INCLUDING AU	THOR, TITLE,	DATE, PERTINI	ENT PAGES, E	TC.)		
MM	*				of the function of the June of the June 19 of the function of the June 19 of the			e	
1000		<u> </u>							
	*	Chemical Abst	racts, vol. 115, No.	. 15. 14.October 1	1991 (1991-10-14)	Columbus Ohio,	US; abstrac	et no.	
		inhibitors on a	en Ekkenard, et al. ctivity of dinentidy	., Dipepiiayi pep l nentidase IV and	otidase IV in the imi d proliferation of hi	mune sysiem. Ej uman lvmphocvti	es." Seite 3	ijic enzyme 7:	
		XP002114197	Zusammenfassung	& Biol. Chem. F	Hoppe-Seyler, BD.	372, Nr. 5, 1991	, Seiten 305	-311.	
	*	Chemical Abst	racts, vol. 126, No.	. 2, 13. January 19	997 (1997-01-13) C	Columbus, Ohio,	US; abstrac	t no.	
		16161j, Stoeck	el, A., et al., "Com	ipetitive inhibitioi das "Seite 241: X	n of proline specific XP002114198 Zusai	c enzymes by ami mmenfassiing &	<i>ino acid</i> PEPT: Che	m Struct	
		Biol., Proc. An	n.Pept.Symp., Nr. 1	14, 1995, Seiten 7	709-710.				
	*	Chemical Abst	racts, vol. 118, No.	. 25, 21. June 199	3 (1993.6.21) Colu	mbus, Ohio, US	; abstract N	o. 255342k,	
		Seite 933, XP0 (1992.11.20).	02114199 Zusamn	nentassung & JP	04 334357 A (Fujer	rebio inc) 20. No	ovember 195	92	
	*	Thorens, B., et			the Control of Insul	lin Secretion in t	he Normal S	State and in	
	 NIDDM," Diabets 42:1219-1225 (1993). Orskov, C., et al., "Proglucagon Products in Plasma of Noninsulin-dependent Diabetics and Nondiabetics 							diabetic	
	*	Controls in the	Fasting State and	After Oral Gluco	se and Intravenous	Arginine," J. C.	lin. Invest. 8	7 :415-423	
ļ	1	(1991).	(i) 1 C	T-1	Det Tuest I I	ha Dintidul Dant	idasa IV (C)	726)	
	*		., "Improved Gluce Thiazolidide," Met		Rats Treated with the 89 (1999).	пе тірнауі Рерп	ause IV (CL)2Uj	
	*	Winslow, R., "	Novartis Drug Alt	ers Picture for Di	iabetes," Wall Street	et Journal, Wed.	, December	27, 2000,	
		p. B2.							
	*	Hendrick, G.K., et al., "Glucagon-Like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats," Metabolism Vol. 42, No. 1, pg. 1-6 (Jan. 1993).						accusin	
	*				Peptide-1 by Human ogenous Metabolite			V-	
W	1 / 1/1	,			2	1			
Examiner:	7/1/1.47	111			Date: 6	doz			



 \bigcirc

Sheet 4 of 5

		<u>~~</u>				neet 4 of		
		PT& 1449		ATTY DOCKET NO. SERIAL NO. 09/682,968				
INFORMA	ATION DISC	CLOSURE ST.	ATEMENT					
				APPLICANTS: Hans-Ulrich De	muth, et al.			
				FILING DATE: ART UNIT:				
				November 2, 2001		1646		
			UNITED STAT	ES PATENT DOCUMENTS				
		CUMENT UMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR	
			FOREIGN	PATENT DOCUMENTS		<u> </u>		
					CI ACC	CIID	TEDANI	
		CUMENT UMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N	
	OTHER D	OCUMENTS (INCLUDING A	UTHOR, TITLE, DATE, PERTI	NENT PAGES, E	TC.)	<u></u>	
MM	*	 716, pp. 355-362 (1995). Nauck, M.A., et al., "Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in type 2 (Non-insulin-dependent) Diabetic Patients," Diabetologia 36:741-744 (1993). Gutniak, M.K., et al., "Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM," Diabetes Care 17:1039-1044, (September 1994). Ansorge, S., et al., "Membrane-bound peptidases of lymphocytes: Functional implications," Biomed. Biochim, Acta 50 (1991) 4-6, pp. 799-807. Demuth, Hans-Ulrich, "Recent Developments in Inhibiting Cysteine and Serine Proteases," J. Enzyme Inhibition, 1990, Vol. 3, pp. 249-278. Dodge, R.W., et al., "Folding and Unfolding Kinetics of the Proline-to-Alanine Mutants of Bovine Pancreatic Ribonuclease A," Biochemistry 1996, 35, pp. 1548-1559. Gomez, S., et al., "Relationship between endo- and exopeptidases in a processing enzyme system: Activation of an endoprotease by the aminopeptidase B-like activity in somatostatin-28 convertase," Proc. Natl. Acad. Sci. USA, Vol. 85 pp. 5468-5472, August 1988. Hegen, M., et al., "The T Cell Triggering Molecule Tp103 is Associated with Dipeptidyl Aminopeptidase IV Activity," The Journal of Immunology, vol. 144, pp. 2908-2914, No. 8, April 15, 1990. Ishiura, S., et al., "Identification of a putative amyloid A4-generating enzyme as a prolyl endopeptidase," Federation of European Biochemical Societies, Vol. 260, No. 1, pp. 131-134, January 1990. 						
	On 1	peptide-1 (7-36 serum," Eur. J. Pederson, R.A. Dipeptidyl Pep	b) amide, peptide of Biochem., 214, p., et al., "Improved tidase IV Inhibito t al., "Proline mo	peptidase IV hydrolyses gastric inh histidine methionine and is respons op. 829-835 (1993). d Glucose Tolerance in Zucker Fat r Isoleucine Thiazolidide," Diabete tifs in peptides and their biological	ible for their degro ty Rats by Oral Ad es, Vol. 47, August	adation in h ministration : 1998 pp. 1	uman 1 of the 253-1258.	
Examiner:				Date:	2010			



Sheet 5 of 5

		0/_			Sheet 5 of			
INFORM	FORM PTO-1449 ATION DISCLOSURE ST	ATEMENT	ATTY DOCKET NO. SERIAL NO. 09/682,968					
			APPLICANTS Hans-Ulrich Demuth, et al.					
			FILING DATE: November 2, 2001	ART UNIT: 1646				
		UNITED STAT	TES PATENT DOCUMENTS	1				
EXAM. INITIAL	DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR		
		FOREIGN	PATENT DOCUMENTS			<u> </u>		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N		
MM	No. 2, April 1 Kessler, Von I (1982) pp. 509 Kirschke, H., pp. 1583-1634 Yaron, A., et a	8, 1980, pp. 111-1 Horst, "Konforma 0-520. et al., "Proteinase al., "Proline-Depe	ific Endo- and Exopeptidases," Mole 27 tion und biologische Wirkung von cyc s 1: lysosomal cysteine proteinases," endent Structural and Biological Propy and Molecular Biology, 28(1), pp.	Clischen Peptiden Protein Profile, Derties of Peptide	Vol. 2, Issue	Chem. 94 e 14, 1995		
Examiner:	M. Alv		Date: 6	20/00	2			